Abaloparatide acetate salt structure
|
Common Name | Abaloparatide acetate salt | ||
---|---|---|---|---|
CAS Number | 247062-33-5 | Molecular Weight | 3960.6399 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C174H299N56O49 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Abaloparatide acetate saltAbaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis[1][2]. |
Name | abaloparatide |
---|---|
Synonym | More Synonyms |
Description | Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis[1][2]. |
---|---|
Related Catalog | |
In Vitro | Abaloparatide (0-100 nM; 40 min) 增强 MC3T3-E1 细胞中的 Gs/cAMP 信号传导和 β-arrestin 募集[1]。 Abaloparatide (0-100 nM) 在 U2OS 细胞中以剂量依赖性方式有效诱导 PTHR1 内化,EC50 值为 0.8 nM[1]。 |
In Vivo | Abaloparatide (20-80 µg/kg;皮下注射;每日一次,持续 30 天) 可增强小鼠的骨形成和皮质结构[1]。 Animal Model: 16-week-old wild-type (WT) female C57BL/6J mice[1] Dosage: 20-80 µg/kg Administration: S.c.; daily for 30 days Result: Efficiently expanded cortical thickness (Ct. Th) at both doses of 20 and 80 µg/kg/day by 17% and 18%, respectively, increased P1NP levels to 227% and 407% at 20 and 80 µg/kg/day, respectively. Animal Model: Female Sprague-Dawley rats (age 22 weeks)[2] Dosage: 1 µg/kg, 5 µg/kg, 25 µg/kg Administration: Subcutaneous injection; daily; for 12 months Result: Increased biochemical bone formation markers, histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces. Induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) was increasing 25%. |
References |
Molecular Formula | C174H299N56O49 |
---|---|
Molecular Weight | 3960.6399 |
Storage condition | -20°C |
abaloparatide |